

April 7, 2023
IWAKI SEIYAKU CO., LTD.

Announcement on Transfer of Manufacturing, Marketing Approval, Sales, and Distribution of “Bonalfa[®] / Bonalfa[®] High”

IWAKI SEIYAKU CO., LTD. (IWAKI SEIYAKU) announces that IWAKI SEIYAKU and TEIJIN PHARMA Limited agreed to transfer of manufacturing and marketing approval for “Bonalfa[®] Ointment 2mg/g, Bonalfa[®] Cream 2mg/g, Bonalfa[®] Lotion 2mg/g” and “Bonalfa[®] High Ointment 20mg/g, Bonalfa[®] High Lotion 20mg/g” (Bonalfa[®]). IWAKI SEIYAKU will start the manufacturing, distributing, and marketing of this product in Japan from July 1, 2023.

Bonalfa[®] is dermatological agents containing Tacalcitol Hydrate which is an active vitamin D₃. Bonalfa[®] is indicated for psoriasis, ichthyosis, palmoplantar pustulosis, palmoplantar keratosis, and pityriasis pilaris, Bonalfa[®] High is indicated plaque psoriasis.

IWAKI SEIYAKU is a pharmaceutical company focused on manufacturing and distribution of the ethical and OTC drugs. The company is especially active in the generic market of medical care for dermatology. We believe that the succession of Bonalfa[®] and Bonalfa[®] High will lead to the strengthening of our product portfolio. IWAKI SEIYAKU expands its brands and product portfolio in the future, and will make all the efforts to supply this product stably.

Contact:

IWAKI SEIYAKU CO., LTD.

Corporate Planning Department

E-mail : iyakukaihatsu2011@iwakiseiyaku.co.jp